Personalized nutrition guided by continuous glucose monitors for people with type 2 diabetes
Official title: Individualized Diabetes Education Assisted by CGM (IDEA-CGM)
Run by University of Minnesota · NCT06784375 · Data updated 2026-11-12
This study tests whether using continuous glucose monitor feedback to personalize medical nutrition therapy helps adults with type 2 diabetes (HbA1c 6.8–8.5%) improve blood sugar control.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 72 (estimated) |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Status | Recruiting |
| Started | July 14, 2025 |
| Main results expected | September 15, 2027 |
| Study ends | September 15, 2027 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT06784375 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with type 2 diabetes, HbA1c between 6.8% and 8.5%, BMI ≥25 kg/m2 (or ≥23 kg/m2 for Asian participants), eGFR ≥60 ml/min/1.73 m2, not using insulin, sulfonylureas, or meglitinides, and willing to attend visits at the University of Minnesota.
✕Probably not a fit
People using insulin or sulfonylureas, with type 1 diabetes, significant kidney impairment, low BMI, recent weight change, pregnancy, breastfeeding, or anemia are excluded and unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with type 2 diabetes and HbA1c 6.8–8.5% who are not treated with insulin or certain diabetes drugs are randomized to one of four groups combining unblinded or blinded continuous glucose monitoring (CGM) with or without personalized medical nutrition therapy. Participants in the personalized nutrition arms receive tailored dietary advice based on their CGM glucose patterns, while control arms use CGM without receiving nutrition counseling. The trial compares changes in glycemic measures such as HbA1c and CGM-derived time-in-range and postprandial glucose over the intervention period. The study is conducted at the University of Minnesota and requires in-person visits for enrollment and follow-up.
Why it matters
Potential benefit: If successful, personalized CGM-guided nutrition could improve glucose control and reduce high blood sugar spikes without adding medication.
How similar studies have gone: Previous smaller trials and pilot studies have shown that CGM-informed dietary feedback can reduce postprandial glucose excursions and improve time-in-range, but large definitive trials are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * at least 18 years of age * previous diagnosis of T2DM * HbA1c of 6.8-8.5% Exclusion Criteria: * type 1 diabetes mellitus * treatment with insulin, sulfonylurea, or meglitinide * use of nondiabetic medications that affect blood glucose control (such as corticosteroids) * BMI \<25 kg/m2 or \<23 kg/m2 for participants who self-identify as Asian * weight change \>5 pounds in the 3 months prior to study enrollment * estimated glomerular filtration rate \<60 ml/minute/1.73 m2 * pregnancy or immediate plans to become pregnant 8) breastfeeding 9) anemia (which would affect measurement of HbA1c) 10) changes to glucose lowering medications, including change in dose, in the 3 months prior to enrollment 11) presence of any disease that would make adherence to the protocol difficult."
Where it's running
-
University of Minnesota
Minneapolis, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Anne Bantle — University of Minnesota
- Study coordinator: Anne Bantle
- Email: bant0015@umn.edu
- Phone: 612-625-8673
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acute Blood Flow Restriction Walking in Type 2 Diabetes
This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.
-
Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin
This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.
-
Differentiating heart disease in autoimmune vs. type 2 diabetes
This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.
-
Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses
This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.
-
Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar
This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.
-
Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes
This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.